Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Shanghai Junshi Biosciences Co., Ltd. Class H ( (HK:1877) ) has provided an announcement.
Shanghai Junshi Biosciences Co., Ltd. has successfully completed the placement of 41,000,000 new H Shares, raising approximately HK$1,026 million in net proceeds. This capital will primarily be used for the development of innovative drugs, including several bi-specific antibodies and fusion proteins, while also supporting general corporate purposes. The completion of this placement increases the company’s total issued shares and strengthens its position in the biopharmaceutical industry by enhancing its financial resources for ongoing and future projects.
The most recent analyst rating on (HK:1877) stock is a Hold with a HK$12.00 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
More about Shanghai Junshi Biosciences Co., Ltd. Class H
Shanghai Junshi Biosciences Co., Ltd. is a biopharmaceutical company based in China, focusing on the development of innovative drugs. The company specializes in creating therapies for cancer and autoimmune diseases, with a market focus on bi-specific antibodies and fusion proteins.
Average Trading Volume: 5,791,608
Technical Sentiment Signal: Buy
Current Market Cap: HK$33.7B
For detailed information about 1877 stock, go to TipRanks’ Stock Analysis page.